Healthcare entity
Every one of those 1 sits in a single category, medical-devices. Sera Prognostics is most often covered alongside Austin Aerts, which appears in 1 of these 1 story. Each story carries 6 original sources on average, compared with 3 for the broader beat in this window.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, medical-devices. Sera Prognostics is most often covered alongside Austin Aerts, which appears in 1 of these 1 story. Each story carries 6 original sources on average, compared with 3 for the broader beat in this window. At 6, the average consequence score sits above the same-window beat average of 5.9. Sera Prognostics appears in 1 tracked Healthcare story from March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Sera Prognostics. Shared-story counts are live from our verified record — not editorial picks.
Runway Horizon
Current capital projected to fund operations through significant commercial milestones.
2026 Target
Goal to reach 15-17 states and operate 5-7 live partner programs.
Q4 Earnings Call
Management outlines pivot from R&D to commercial scaling and state-level engagement.
Fiscal Year End
Sera concludes 2025 with $95.8M cash and successful PRIME study publication.
Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. Following the successful publication of its PRIME study—which demonstrated a 56% reduction in very preterm births—the company is aggressively shifting its focus toward state-level payer engagement and commercial scaling.
Sera Prognostics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
